Tumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant subtypes based on core gene signatures. However, molecular signaling in glioma stem cells (GSCs) in individual HGG subtypes is poorly characterized. Here we identified and characterized two mutually exclusive GSC subtypes with distinct dysregulated signaling pathways. Analysis of mRNA profiles distinguished proneural (PN) from mesenchymal (Mes) GSCs and revealed a pronounced correlation with the corresponding PN or Mes HGGs. Mes GSCs displayed more aggressive phenotypes in vitro and as intracranial xenografts in mice. Further, Mes GSCs were markedly resistant to radiation compared with PN GSCs. The glycolytic pathway, comprising aldehyde dehydrogenase (ALDH) family genes and in particular ALDH1A3, were enriched in Mes GSCs. Glycolytic activity and ALDH activity were significantly elevated in Mes GSCs but not in PN GSCs. Expression of ALDH1A3 was also increased in clinical HGG compared with low-grade glioma or normal brain tissue. Moreover, inhibition of ALDH1A3 attenuated the growth of Mes but not PN GSCs. Last, radiation treatment of PN GSCs up-regulated Mes-associated markers and downregulated PN-associated markers, whereas inhibition of ALDH1A3 attenuated an irradiation-induced gain of Mes identity in PN GSCs. Taken together, our data suggest that two subtypes of GSCs, harboring distinct metabolic signaling pathways, represent intertumoral glioma heterogeneity and highlight previously unidentified roles of ALDH1A3-associated signaling that promotes aberrant proliferation of Mes HGGs and GSCs. Inhibition of ALDH1A3-mediated pathways therefore might provide a promising therapeutic approach for a subset of HGGs with the Mes signature.
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cancer stem cell | epithelial-to-mesenchymal transition | glioblastoma multiforme | glioblastoma | proneural-to-mesenchymal transition A hallmark of malignant high-grade gliomas (HGGs), including anaplastic glioma and glioblastoma multiforme (GBM), is their intrinsic resistance to current therapies that leads to extremely poor clinical outcomes (1) . Even patients with welldemarcated tumors in noneloquent areas that allow maximal gross total removal at surgery and respond well to initial combined therapies inevitably develop subsequent tumor recurrence with minimal survival (2) . Therefore, there is an urgent need to better understand the underlying mechanisms of such malignancy, thereby providing an opportunity to develop novel therapies and approaches to treat patients with aggressive HGGs.
It is established that multiple genetic and metabolic pathways create intricate networks to facilitate cross-talk between oncogenic and oncometabolic pathways that contribute to tumor progression and therapy resistance of human cancers, including HGGs (3). Recent genomewide transcriptome analyses suggest that HGGs can be divided into four clinically relevant subtypes: proneural (PN), neural, classic, and mesenchymal (Mes) HGGs (4, 5) . Distinct signals are activated in these individual HGG subtypes that may account for the observed differential responses to therapy. Therefore, therapeutic strategies for HGGs should be designed based on tumor subtype instead of applying them to all patients with HGGs (6) .
HGG tumors are composed of heterogeneous tumor cell populations that include tumor cells with stem cell properties termed glioma initiating/propagating cells or glioma stem cells (GSCs) (7) . The unique properties of GSCs are considered to contribute to the therapeutic resistance of HGG (8, 9) . Thus, understanding and targeting tumor-propagating GSCs could be beneficial in developing effective strategies that overcome therapeutic resistance of HGG. Given the distinct gene sets and signaling pathways that are differentially expressed in each subtype of HGG (4, 5) , GSCs in each subtype may also harbor distinct and dysregulated pathways that render their unique phenotypes in tumor growth, progression, and resistance to therapy.
In this study, we tested a hypothesis that HGG subtypes also contain distinct GSC subtypes that could be differentiated by transcriptome array analyses, and we then determined individual expression and phenotypic signatures in two mutually exclusive GSC subtypes.
Results

GSC Cultures Derived from HGG Surgical Specimens Displayed Two
Distinct Stem Cell-Related Phenotypes In Vitro. We collected 40 patient specimens of HGGs from surgeries for patients with HGGs and established 19 HGG-derived tumor cultures in defined serumfree medium that enriches tumorigenic self-renewing and multipotent GSCs as previously described (Table S1 ) (10) . Under these culture conditions, we observed two phenotypically different GSC cultures with distinct morphologies. One set of GSC cultures (n = 10) displayed round neurosphere-like floating aggregates (cluster 1), and the other set (n = 9) formed irregular-shaped floating aggregates with some adherent cells on the bottom of the culture dish (cluster 2; Fig. S1A ). Immunocytochemistry with several stem cell-associated markers demonstrated that GSCs in cluster 1 were highly positive for Sox2 (markers for PN HGGs) and capable of differentiating into GFAP-positive glial cells and TuJ1-positive neuronal cells, whereas GSCs in cluster 2 were positive for CD44 but negative for Sox2 (Fig. S1B) . Additionally, both types of GSCs retain their multipotency properties ( Fig. S1 C and D) . However, no single factor that correlates with a statistically significant difference distinguishes the clinical characteristics of patients with the HGGs from which these two groups of GSCs were derived.
Distinct Expression Profiles of mRNA Distinguish Mes from PN GSC Subtypes. Recently, two reports proposed the existence of two GSC subtypes as determined by microarray based gene expression profiles (11, 12) . To investigate whether our GSC samples display two distinct expression profiles in a similar manner, we performed transcriptome microarray analysis of 27 GSC samples (triplicate samples from nine patient-derived GSC cultures), as well as cells comprising human astrocytes, fetal neural progenitors, and five glioma cell lines. For expression signature analysis, we performed a differential expression analysis of GSCs (PN vs. Mes) and found 5,796 genes to be differentially expressed (false discovery rate < 0.05; Fig. S2A ). As shown in the heat map of differentially expressed genes in Fig. 1A , one group showed high expression of what are considered PN-associated genes and the other with Mes-associated genes. Our samples cluster accordingly with the PN and Mes HGG subtypes from the Philips dataset, as shown in the hierarchical cluster analysis (Fig. 1B , Upper) (4). Furthermore, 3,376 genes (FDR < 0.05) were found differentially expressed between the PN and Mes samples in the TCGA dataset (Fig. 1B, Lower) . A total of 1,986 differentially expressed genes were present in both analyses (GSCs and TCGA datasets). Interestingly, fewer genes were found statistically significantly and differentially expressed in the TCGA dataset than in our dataset, a fact that might be explained by the higher heterogeneity of TCGA tumor samples (Fig. S2B ). To validate these microarray results, we performed quantitative real-time-PCR (qRT-PCR) analysis of some of the most highly differentially expressed genes (lowest P value). The data shown in Fig.  1C highlight the consistent results of expressions between the microarray and qRT-PCR analysis with the PN-associated genes (CD133, Olig2, Sox2, and Notch1) and the Mes-associated genes (CD44, Lyn, WT1, and BCL2A1) in PN and Mes GSCs (4, 5) , respectively. The expression of these representative PN and Mes genes displayed similar, if not identical, expression patterns in the matched original tumors and their derived tumor spheres (Fig.  S3A ). We also found that within the PN or Mes groups, the GSC samples were better correlated with each other than the TCGA samples, likely due to the higher heterogeneity among the TCGA tumors (Fig. 1B) . As for isocitrate dehydrogenase 1 (IDH1) mutation status, all four PN and two Mes GSCs we sequenced were IDH1 WT (Fig. S3B ).
Mes GSCs Show More Aggressive Phenotypes than PN GSCs In Vitro and In Vivo. Next, we investigated whether PN and Mes GSCs display any differences in cellular and tumorigenic behaviors. As shown in Fig. 2A , under identical growth conditions, Mes GSCs showed higher potential for in vitro cell growth than PN GSCs ( Fig. 2A; Fig. S4 ). We then implanted individual PN GSCs (84, AC17, and AC20) or Mes GSCs (83, 326, and 1123) into the brains of immunocompromised mice. As shown in Fig. 2 B and C, mice that received Mes GSCs succumbed to intracranial GBM-like tumors within 18 d, with a median survival of 15 d after implantation. In contrast, mice that received PN GSCs developed brain tumors at a much slower rate, with a median survival of 123 d. Mes GSC-derived brain tumors contained multiple large hemorrhagic lesions and abundant tumor vessels, as well as tumor-associated necrosis, whereas PN GSC-derived tumors showed minimal or no increase of angiogenesis or necrosis compared with the adjacent normal brain (Fig. 2B, arrows) .
We then assessed the expression of CD133 and CD44, two cell surface proteins that often associate with cancer stem cells, in these GSCs by FACS analysis (13, 14) . As shown in Fig. 2D , most PN GSCs were positive for CD133, whereas Mes GSCs presented with only minimal to undetectable CD133-expressing cells. Conversely, the majority of Mes GSCs were positive for CD44, whereas PN GSCs had minimal to modest levels of CD44 expression. We next tested whether these data recapitulate the expression of the original clinical HGG tumors from which these GSCs were derived and whether these expression patterns are maintained in the intracranial xenografts. As a PN-associated marker for immunohistochemistry (IHC), we used Olig2 because IHC staining for CD133 did not reliably correlate with our FACS results of dissociated tumor cells. Most of the original HGG samples that gave rise to PN GSCs expressed the PN marker Olig2 at high levels but were negative or only faintly stained for the Mes marker CD44 ( Fig. 2E; Fig. S5 ). In contrast, those HGG specimens that gave rise to Mes GSCs exhibited high levels of expression of CD44 but minimal levels of Olig2. Interestingly, most of the GSC-derived intracranial xenograft tumors maintained similar patterns of immunoreactivity to Olig2 and CD44 (six of eight samples). Taken together, these results suggested two distinct GSC subtypes established from clinical HGG samples retained, at least to a major extent, the expression signatures of the original HGG tumors and recapitulated the major phenotypes of the original clinical HGGs in their xenograft brain tumors. 
Aldehyde Dehydrogenase 1A3 Activity Is Markedly Elevated in Mes
GSCs Compared with Mes Non-GSCs and PN GSCs. Based on the transcriptome array analyses, we found that a total of 5,796 genes are differentially expressed between our PN and Mes GSCs (Fig.  S2A) . Pathway enrichment analysis [Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways] for all differentially expressed genes identified the pathway of glycolysis and gluconeogenesis containing aldehyde dehydrogenase (ALDH) genes to be the most significantly enriched in Mes GSCs (P = 0.000315; Fig. 3A ). Furthermore, glycolytic activity was significantly elevated in Mes GSCs (n = 4) compared with PN GSCs (n = 4; Fig. 3B ). In particular, four key enzymes in this pathway, PCK2, LDHC, ALDH1A3, and ALDH9A1, were significantly up-regulated in Mes GSCs, whereas ACSS1 is expressed at higher levels in PN GSCs (Fig. 3C) .
Of note in the transcriptome analyses, ALDH1A3, an isoenzyme of ALDH1 in the glycolysis and gluconeogenesis pathway, showed an ∼150-fold increase in mRNA levels in Mes GSCs compared with that in PN GSCs (Fig. 4A) . Thus, we examined the expression of all 19 members of the ALDH family in these GSCs and found that only ALDH1A3 was up-regulated in Mes GSCs compared with PN GSCs (Fig. S6A) . Next, we investigated ALDH1 activity of these GSCs using FACS analysis after staining with Aldefluor (Fig. 4B ). Aldefluor is a nontoxic substrate that diffuses into living cells and then is broken down to the fluorescent molecule Bodipy-aminoacetate by ALDH1. Thus, the amount of intracellular accumulated fluorescent reaction product is directly proportional to intracellular ALDH1 activity (15) . As shown in Fig.  4B and Fig. S6B , ALDH1 activity-high (ALDH1-high) cells are only found in Mes GSCs (n = 3) but not in PN GSCs (n = 3) or nonGSCs derived from Mes GSCs (n = 3). We then assessed whether ALDH1 activity in Mes GSCs correlates with the stemness of these GSCs (e.g., in vitro clonality and bipotent capacity) by a clonal sphere formation assay. After separation of Mes GSCs into ALDH1-high cells and ALDH1-low cells by FACS, ALDH1 activity positively correlated with the in vitro clonogenic potential of ALDH1-high GSCs (Fig. 4C ). Then we performed bipotency tests of ALDH1-high and ALDH1-low cells and determined whether FACS-sorted Mes ALDH1-high and ALDH1-low cells give rise to both ALDH1-high and ALDH1-low cells 7 d following FACS separation ( Fig. 4D; Fig. S6C ). Although the majority of ALDH1-low cells remained as ALDH1-low cells (92.1-95.5%), ∼16.2-28.3% of the sorted ALDH1-high cells retained the ALDH1-high phenotype, similar to the proportions within the unsorted Mes GSCs. These results suggest that ALDH1 activity corresponds to bipotency of Mes GSCs in vitro. Next, we tested whether the ALDH1 activity is required for growth of Mes GSCs in vitro. When various GSCs were incubated with the ALDH1 inhibitor diethylaminobenzaldehyde (DEAB) (15), Mes GSCs, but not PN GSCs, showed marked decreases in in vitro growth ( Fig. 4E; Fig. S7A ). We then used two shRNA constructs to deplete ALDH1A3 in three PN GSCs and three Mes GSCs. As shown in Fig. 4F and Fig. S7B , knockdown of ALDH1A3 by shRNA constructs markedly inhibited the growth of Mes GSCs yet had minimal impact on the growth of PN GSCs. Decreased expression of ALDH1A3 by ALDH1A3 knockdown was confirmed in both PN and Mes GSCs ( Fig. 4F; Fig. S7C ).
Collectively, ALDH1A3 appears to be required for the in vitro growth of Mes GSCs but not PN GSCs. To further demonstrate clinical relevance of ALDH1A3 expression, we performed IHC staining for ALDH1A3 expression in a collection of 76 clinical glioma samples containing WHO grade II-IV tumors, as well as adjacent normal brain tissues ( Fig. 4G; Fig. S7D ). In sharp contrast to the observed negative expression of ALDH1A3 in 15 normal brain tissues and 7 low-grade glioma tissues, expression of ALDH1A3 in HGG tissue specimens was markedly increased (n = 51; Fig. 4G ). Taken together, these results demonstrate that ALDH1A3 is highly expressed in clinical HGG tumor specimens and suggest that ALDH1A3 could be a unique functional biomarker for Mes GSCs.
Mes GSCs Are More Resistant to Radiation Treatment than PN GSCs In
Vitro. A recent study demonstrated that the mesenchymal phenotype is a hallmark of tumor aggressiveness in brain tumors (16) . Thus far, our in vitro and in vivo data suggest that Mes GSCs display a more aggressive tumor phenotype than PN GSCs (Fig. 2) . Therefore, we postulated that Mes GSCs could be more resistant than PN GSCs to radiation treatment, the current firstline therapy for HGGs. Thus, we first examined the expression profiles of several genes involved in the repair of DNA doublestrand breaks, comparing the PN and Mes GSCs by transcriptome microarray and qRT-PCR. Expression of most, if not all, of these DNA damage signaling and DNA repair genes was significantly higher in Mes GSCs than PN GSCs (Fig. 5A) . Furthermore, a striking difference in radiosensitivity was observed between PN and Mes GSCs (n = 11; Fig. 5B; Fig. S8A ). As expected, Mes GSCs were significantly resistant to radiation treatment compared with PN GSCs.
Radiation Treatment Induces Mes-Associated Marker Expression in PN
GSCs. The transition of epithelial tumors to a Mes phenotype plays a critical role in advancing aggressiveness, tumor cell motility, and metastasis in various types of human cancers (17) . Given that Mes GSCs appear to be more radioresistant, we predicted that radiation treatment may induce a shift of the GSC phenotype from PN to Mes [PN-to-Mes transformation (PMT)]. To test this hypothesis, we first performed qRT-PCR and found that Sox2, a PN marker, was decreased, whereas CD44, Vimentin, and CDH1, all of which are mesenchymal markers, increased by radiation treatment of PN GSCs (n = 3; Fig. 5C ). Then we examined the expression of the Mes marker CD44 and the PN marker Sox2 in three PN and three Mes GSCs before and after radiation treatment in vitro ( Fig. 5D; Fig. S8B ). Although the Mes GSCs (n = 3) did not show any detectable difference in the expression of these markers when comparing expression before and after radiation (Fig. S8 B and C) , all three PN GSCs (n = 3) showed a marked increase in the expression of CD44 and an appreciable decrease in expression of Sox2 after radiation treatment, suggesting radiation may induce expression of the Mes signature in PN GSCs, leading to PMT in these HGG-derived PN GSCs ( Fig.  5D; Fig. S8D ). Because ALDH1A3 is aberrantly up-regulated in Mes GSCs compared with PN GSCs (Fig. 4) , we examined whether ALDH1 is required for the putative PMT in these GSCs. Treatment with the ALDH1 inhibitor DEAB before radiation for PN GSCs (n = 3) blocked the shift of expression of Sox2 and CD44 in the treated PN GSCs ( Fig. 5D; Fig. S8D ), suggesting that inhibition of ALDH1 attenuates radiation-induced transformation of PN GSCs into Mes GSCs. Taken together, these data suggest that radiation treatment of PN GSCs induces expression of Mesassociated markers and inhibition of the operational Mes GSC marker ALDH1A3 in irradiated PN GSCs attenuates their transformation into Mes GSCs.
Discussion
In our analysis of well-characterized clinical HGG-derived GSCs, we report the following findings. First, we are able to classify two distinct tumor-derived GSC subtypes in HGGs (PN GSCs and Mes GSCs) by genomewide transcriptome microarray analysis, as well as in vitro and in vivo tumor growth assays. Second, genes involved in glycolysis and gluconeogenesis pathways including ALDH family genes, in particular ALDH1A3, are significantly up-regulated in Mes GSCs compared with PN GSCs. Third, activities of ALDH1, the enzyme that catalyzes the conversion of acetate from acetaldehyde, is markedly increased in Mes GSCs but not PN GSCs. Fourth, inhibition of ALDH1 by a pharmacological inhibitor or shRNA knockdown of ALDH1A3 attenuates PMT and in vitro growth of Mes GSCs. Fifth, ALDH1A3 is highly expressed in clinical HGGs but not in lowgrade glioma or normal brain samples. Sixth, Mes GSCs display a significantly higher radioresistance, with markedly elevated levels of expression of genes associated with DNA repair. Last, irradiation induces transformation of PN GSCs into a Mes-like GSC phenotype (PMT) that is highly resistant to radiation treatment, and inhibition of ALDH1 reverses the radiation-resistant phenotype of Mes GSCs. Taken together, our data suggest that subtypes of GSCs in clinical HGG tumor tissues are identifiable by their in vitro and in vivo behaviors, as well as their global mRNA expression profiles. Up-regulation of ALDH1A3 and DNA repair genes not only distinguishes Mes GSCs from PN GSCs but also contributes to the irradiation-induced PMT.
One novelty of this study is the significance related to our identification of elevated expression of ALDH1A3 in Mes GSCs. First, ALDH1A3 can be a potentially useful biomarker for Mes GSCs. The ALDH gene superfamily is composed of 19 isoenzymes, and their expression appears to be cancer type dependent (18) . We found that most Mes GSCs do not express the commonly used GSC marker CD133. Instead, of all 19 members of the ALDH gene family, the expression level of ALDH1A3 is increased up to 150-fold in Mes compared with PN GSCs. Additionally, ALDH1 has been recently recognized as a surrogate marker for cancer stem cells (CSCs), and knockdown of ALDH1 inhibited CSC growth and sensitized CSCs to chemotherapies in various types of human cancers including breast (19) , colon (20) , and pancreatic (18) cancers. Consistent with these reports, we demonstrate that ALDH1A3 could be a biomarker for Mes GSCs in HGG. Second, increased ALDH1 activity in Mes GSCs is associated with stem cell properties. This observation is clinically relevant because the increased ALDH1 expression correlates with malignancy of glioma in patients. Third, up-regulated ALDH1A3 could also be a potential biomarker to indirectly monitor lipid metabolism in gliomas. Activated cell metabolism (e.g., glycolysis) in cancer cells play critical roles in rendering malignancy and poor responses to therapies of malignant gliomas (21) . In the clinic, 18 F-fludeoxyglucose (FDG) PET is routinely used to evaluate increased glucose consumption and glycolysis in tumors. We found that ALDH1A9 and ALDH1A3, the enzymes that catalyze conversion of acetaldehyde into acetate, are markedly increased in Mes GSCs. Detection of malignant HGG by 11 C-acetate PET based on increased activity of these two enzymes has been reported recently (22) . Thus, a potential clinical application of 11 C-acetate PET would be useful for evaluation of subtypes of human HGGs.
We also demonstrate a potential role for ALDH1A3 in radiation-induced PMT. Previous studies described that in some, if not all, GBMs, tumor recurrence after failure of standard therapies is accompanied with a phenotypic shift from PN to Mes tumors (4). Activated MET activity in Mes HGGs was shown to induce a program reminiscent of the epithelial-to-mesenchymal transition and enhanced Mes features (23) . In this study, we revealed that such a PMT also occurs in GSCs. We found that PN GSCs are more sensitive to radiation than Mes GSCs, and radiation treatment of PN GSCs down-regulated PN markers and up-regulated Mes markers, suggesting radiation-induced PMT. In contrast, radiosensitivity of individual GSCs did not show any statistically significant correlation with tumor grade, despite the distinct genetic background of WHO grade III gliomas compared with grade IV tumors (e.g., 1p/19q LOH in malignant oligodendrogliomas). Our observation of more PN GSCs derived from grade III tumors including oligodendrogliomas and more Mes GSCs derived from grade IV GBMs demonstrates the significance of a Mes signature, specifically in GSCs. The molecular insight of this unique phenomenon warrants further investigation. Moreover, our results do suggest several open questions that will require further discussion. First, during this study, we noticed that some of the grade III tumor samples (e.g., 1123) gave rise to Mes GSCs, and some of the recurrent GBM (e.g., 347, 816, and 528Rec) after failure of whole brain radiation gave rise to PN GSCs. This result may reflect the existence of both PN and Mes GSC subtypes within individual tumors. Second, the clinical significance of PN and Mes signatures in HGGs needs further indepth investigation. Although contribution of a Mes signature in glioma (and other cancers) for aggressiveness and poorer prognosis of affected patients is also well recognized, a recent study by Sturm et al. (24) reported that a small subset of PN GBM (after removing IDH1 mutant samples) has a worse prognosis. It appears still debatable which subtype of gliomas has a better or worse prognosis. Third, although we observed a clear increase of Mes-associated genes and proteins in irradiated PN GSCs, further investigation is needed to determine whether radiation treatment causes a complete and irreversible transformation from the PN to Mes phenotype. In fact, both the Phillips study and the Verhaak study identified all three (or four) subtypes in newly diagnosed and recurrent tumors (4, 5) . In addition, our data do not rule out the possibility that radiating mixed populations in PN GSCs could potentially allow for a small subset of radiation-resistant Mes-like cells to preferentially survive and emerge as the dominant population under our experimental condition (radiation). In fact, preirradiated PN GSCs contain a subset of CD44-expressing/Sox2-negative cells (Fig. 5D) , suggesting that our hypothesis could be at least a potential possibility.
In conclusion, in this study, we identified two mutually exclusive GSCs in HGGs (PN and Mes) with striking phenotypic and genetic differences including aberrantly high expression of ALDH1A3 in Mes GSCs. We also showed that irradiation induces a change of expression of the PN and Mes representative markers indicating a transformation of PN to Mes GSCs and ALDH1A3 is required for this transformation. Collectively, our data provide a set of evidence suggestive of a unique signaling mechanism underlying the transformation of PN GSCs to Mes-like cells and maintenance of stemness of Mes GSCs. Future characterization of the ALDH1-mediated pathways could potentially elucidate novel molecular mechanisms of GSC maintenance and/or propagation and eventually lead to the development of novel and effective molecularly targeted therapies for HGGs.
Materials and Methods
Experimental methods are detailed in SI Materials and Methods. Methods include generation of HGG tumor-derived neurospheres, reagents and antibodies, immunostaining, gene expression profiling and genetic analyses, qRT-PCR and FACS, in vitro cultures, xenotransplantation, glycolysis cellbased assay, IDH1 mutation detection, and statistical analyses. A complete list of cohort demographics is provided in Table S1 .
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SI Materials and Methods
Glioma Tumor-Derived Neurospheres. All of the work related to human tissues was performed at The Ohio State University under an institutional review board-approved protocol according to National Institute of Health (NIH) guidelines. Glioma and normal neurospheres were derived from 19 of high-grade glioma (HGG) samples, 3 fetal brain-derived astrocytes (such as 16wf), and neural progenitors (Table S1) as described previously (1-4) . Surgeries of brain tumor resections were performed by Drs. I. Nakano and E. A. Chiocca at the Department of Neurological Surgery, The Ohio State University (Columbus, OH). Briefly, freshly resected glioma tumor samples were dissociated into single cells using both mechanical (gently pipet neurospheres with P1000 pipet tips four to five times) and enzymatic methods (TrypLE Express, 1; Invitrogen). The dissociated tumor cells were cultured in DMEM/F12 (Invitrogen) supplemented with B27 (1:50), heparin (5 mg/mL), basic FGF (bFGF) (20 ng/ mL), and EGF (20 ng/mL). Growth factors (bFGF and EGF) were added twice a week. To differentiate glioma stem cells (GSCs), neurospheres were cultured in DMEM/F12 supplemented with 10% (vol/vol) FBS for 10 d. Phenotypic characterization of these primary cultures was performed as described previously (1, 5) . The human fetal neural stem cell sample (16wf) was established at the University of California at Los Angeles as described previously (6) . All of the neurospheres analyzed in this study were cultured <20 passages. In some experiments, various neurospheres were exposed to radiation (5 Gy) after cells were plated at a density of 1 × 10 6 cells/flask 1 d before radiation treatment. Single cells of various neurospheres were also treated with diethylaminobenzaldehyde (DEAB) (100 μM; Sigma) or DMSO as a vehicle control.
Reagents and Antibodies. The following primary antibodies and reagents were used in this study: anti-Nestin (mouse), anti-Sox2 (mouse), anti-Olig2 (rabbit), anti-Vimentin (mouse), and antiSnail (rabbit) antibodies were from Millipore; anti-CD44 (mouse) antibody used for immunocytochemistry (ICC) was from Biolegend; anti-CD44 (mouse) antibody used for immunohistochemistry (IHC) was from Dako; and anti-aldehyde dehydrogenase (ALDH) 1A3 (rabbit) antibody was from Sigma (catalog no. SAB1300933, polyclonal). For ICC, primary antibodies were visualized with Alexa Fluor 488-(green)-conjugated secondary antibodies (Cell Signaling), and nuclei were stained with Hoechst 33342 (blue). B27 (1:50) was from Invitrogen; heparin (5 mg/mL) was from Sigma; and bFGF (20 ng/mL) and EGF (20 ng/mL) were from Pepro Tech. DMEM/F12 and FBS were from Invitrogen. Alizarin Red S Stain Solution (1×) was from Millipore.
ICC and IHC. ICC and IHC were performed as previously described (1) . Samples incubated without primary antibodies were used as negative controls. For IHC, experimental mice were perfused with ice-cold PBS followed by 4% (wt/vol) paraformaldehyde (PFA). Then brains were fixed in 4% (wt/vol) PFA, paraffinembedded, and cut into 10-μm sections. Brain sections were incubated with the indicated primary antibodies overnight at 4°C, followed by incubation with an HRP-conjugated secondary antibody for 1 h at room temperature. Signals were detected using DAB substrate kit (Vector). Nuclei were counter stained with hematoxylin or Hoechst, respectively.
RNA Isolation. Cells were lysed with 1 mL Qiazol lysis reagent. Total RNA was then extracted and purified using the Qiagen RNeasy Mini kit (catalog no. 217004) according to the manufacturer's instructions. After a wash with buffer RWT followed by two washes with buffer RPE, RNA products were eluted from the column with 30 μL RNase-free water. For each cell culture, three independent RNAs were prepared. RNA quality was determined using an Agilent 2100 Bioanalyzer at the Cancer Biomarkers Facility at the University of Pittsburgh Cancer Institute. In all sample preparations, the average RNA integrity number (RIN) was >9.0. RNA concentration was determined using a Nanodrop 2000. For the qRT-PCR analysis of the DNA damage-repair genes, Taqman Gene Expression Assay probes from Life Technologies were used, and β-actin (catalog no. 4352935E) was used as an internal control. Each qRT-PCR assay was performed in a 20-μL volume with 4 μL cDNA, 1 μL Taqman probe, 10 μL TaqMan Fast Universal Master Mix (2×; catalog no. 4367846), and 5 μL of DNase/ RNase-free distilled water. The reactions were performed in an ABI StepOnePlus RT-PCR system according to the manufacturer's protocol. The probe IDs for this study are as follows: ATM, Hs01112307_m1; BRCA1, Hs01556193_m1; BRCA2, Hs00609073_m1; RAD50, Hs00990023_m1; RAD51, Hs00153418_m1; and CDC25C, Hs00156411_m1.
In Vitro Growth Assay. Tumor neurospheres from individual glioma tumor samples were dissociated into single cells, and cell density was quantified by counting viable cells using a hematocytometer following the addition of 10% (vol/vol) Trypan Blue (Invitrogen). Then cells were seeded into 96-well plates containing 100 μL sphere medium at a density of 1,000 cells per well. Alamar Blue (Invitrogen) was added into each well, and cell proliferation was evaluated at different time points according to the manufacturer's protocol.
Limiting Dilution Neurosphere Forming Assay. Tumor neurospheres from individual samples were dissociated into single cells and seeded into 96-well plates ranging from 5 to 1,000 cells seeded per well. Each well contained 100 μL serum-free medium (1). Sphere numbers were then counted at day 3 under an inverted microscope from Optronics equipped with a digital camera. Those aggregates more than 50 μm in diameter were defined as tumorspheres.
Transient Transfection. Culture medium for tumor neurospheres was changed into sphere medium without antibiotics 1 d before transfection. Then tumor neurospheres were transfected with shALDH1A3 using lipofectamine2000. Growth medium was changed 6 h after transfection. The following shRNAs for ALDH1A3 (Sigma) were used in this study: shALDH1A3 clone 1: CCGGGCAACCAATACTGAAGTTCAACTCGAGTTGAACT-TCAGTATTGGTTGCTTTTT; shALDH1A3 clone 2: CCGGG-CCGAATACACAGAAGTGAAACTCGAGTTT CACTTCT-GTG TATTCGGCTTTTT. Cell Sorting of GSCs Using ALDH as a Surface Marker. GSCs were dissociated into single cells followed by immunostaining with or without the selective ALDH1 inhibitor, DEAB (150 μM), according to the manufacturer's protocol (Aldefluor Kit; StemCell Technologies). ALDH1-high and ALDH1-low GSC cells were isolated using a FACSCalibur flow cytometer (BD Biosciences) based on fluorescence signals of these cells. Autofluorescence of the GSCs was gated on GSCs that were treated without anti-ALDH1 antibody or with a specific ALDH1 inhibitor (DEAB, 150 μM).
Glycolysis Cell-Based Assay. A glycolysis cell-based assay kit was used to measure the glycolytic activity in GSC samples according to the manufacturer's instructions. Briefly, GSCs were seeded in a 96-well plate at a density of 1 × 10 4 cells per well in 120 μL of neurosphere medium and cultured overnight in a CO 2 incubator at 37°C. Then we used a new 96-well plate and added 100 μL of the standards into standard wells. Next, 10 μL of supernatant from cultured cell plates and 90 μL of assay buffer (total 100 μL each well) were added in to all wells except standard wells. Then, 100 μL of reaction solution was added into each well including standard wells. After a 30-min incubation at room temperature, the absorbance of each well at 490 nm was read with a plate reader. L-lactate concentrations of each sample was calculated using the corrected absorbance of each sample. Assay buffer and reaction solution mentioned above were prepared based on the manufacturer's kit reagents.
DNA Microarray Analysis. Comparative analysis of mRNA expression was performed using the Human U219 Array Strip and the Affymetrix GeneAtlas system, as per the manufacturer's instructions. Microarray analysis for each of the cell cultures (in triplicate) was accomplished with 100 ng purified total RNA (described above) as the initial material and the corresponding amplified and labeled antisense RNA (aRNA) using an GeneCHip 3′ IVT Express kit (Affymetrix), as described by the manufacturer. The resulting aRNA was fragmented as described by the manufacturer. The labeled aRNAs were then mixed with hybridization master mix, and the hybridization mixtures were then denatured at 95°C for 5 min, followed by 45°C for 5 min, and then kept at 45°C until applied to the hybridization tray (GeneAtlas System; 120 μL hybridization mixture of a cell culture was transferred into a well of a four-well hybridization tray). The array strip was immerse into hybridization mixture and incubated in the Hybridization Station at 45°C for 16 h. After hybridization, the strip was washed and stained in the GeneAtlas Fluidics Station using the GeneAtlas Hybridization, Wash, and Stain Kit (#900720; Affymetrix), and the intensity of each hybridized probe was generated using the GeneAtlas Imaging Station. Raw .cel files from the Human U219 Array Strip were analyzed using the "affy" package in R Bioconductor. The raw data were normalized and summarized using the robust multichip average method (RMA). At this point, each gene is represented by one or more probe sets. The probe sets expressing <75 units for all samples were filtered out for the genes that have other probe sets that are being expressed (>75 units). The selective filtering was performed to avoid getting rid of any gene altogether. For genes represented by multiple probe sets, the probe set with the highest interquartile range (a descriptive statistic used to summarize the extent of the spread of the data) was selected to represent the gene. As a result of the filtering procedure, all genes are represented by a single probe set for further statistical analysis.
In Silico Analysis of Differentially Expressed Genes and Pathways.
Biclustering was performed on all 5,475 differentially expressed genes and 27 samples by independently clustering samples and genes. Euclidean distance and average linkage were used as similarity metric and clustering method, respectively. Clustering was done using the R statistical package (hclust function). Differentially expressed genes were compared with all pathways listed in Kyoto Encyclopedia of Genes and Genomes (KEGG), and the enrichment P value was calculated using the Fisher's exact test. Pathways that had P < 0.05 were considered significantly enriched.
Comparison of Expression Data with The Cancer Genome Atlas
Glioblastoma Multiforme Dataset and Phillips HGG Dataset. The Cancer Genome Atlas (TCGA) gene expression data (level 3) for mesenchymal and proneural tumors (7, 8) were downloaded from the TCGA website (https://tcga-data.nci.nih.gov/tcga/ tcgaDownload.jsp). The Phillips HGG dataset and the inhouse expression data were individually processed as described above, and then batch effects were removed by using the ComBat algorithm (9) . Before comparing TCGA and in-house datasets, a similar procedure was used: datasets were individually processed and the ComBat algorithm (9) was used for removing batch effects. Data for the proneural (PN) and mesenchymal (Mes) signature genes (7) were extracted from both datasets, and hierarchical biclustering performed as described above. Pearson correlation between TCGA and in-house datasets were performed in R ("cor" function).
Mesenchymal Differentiation Assay. Cells were seeded at a density of 5 × 10 4 cells in a six-well plate. After 24 h, cell differentiation was induced with osteogenesis induction medium and adipogenic induction/maintenance medium from Lonza, which was used according to the manufacturer's instructions. Cells were fed every 3-4 d by completely replacing the medium with fresh osteogenesis induction medium. After 3-4 wk, cells were rinsed in PBS, fixed with 4% (wt/vol) PFA for 30 min, and stained with Alizarin Red. Adipocytes were distinguished after 3 wk of adipogenesis differentiation.
For the chondrogenic assay, cell pellets were prepared by spinning down 3 × 10 5 cells in 15 mL polypropylene tubes and were grown in complete chondrogenic medium (Lonza). Cell pellets were fed every 2-3 d by completely replacing the medium with freshly prepared complete chondrogenic medium. After 3-4 wk, pellets were fixed in 4% (wt/vol) PFA and embedded in paraffin. Five-micrometer-thick sections were slide-mounted and stained for glycosaminoglycans with Safranin O.
Isocitrate dehydrogenase 1 Mutation Detection. Genomic DNA was isolated from PN and Mes GSCs using the DNeasy Blood and Tissue kit (Qiagen), according to the manufacturer's instructions. The quantity of isolated DNA was assessed using a NanoDrop 1000 spectrophotometer (Thermo Scientific). For the detection of IDH1 mutations, forward and reverse primers were designed to amplify exon 4 (codon R132) of the isocitrate dehydrogenase 1 (IDH1) gene using primer 3 software (forward primer = 5′-ACCAAATGGCACCATACGA-3′; reverse primer = 5′-GCAAAATCACATTATTGCCAAC-3′) to generate a 130-bp PCR product. PCR amplification was performed using 50 ng of DNA, 0.2 μmol of each primer, and the Ex Taq PCR kit (Takara). The amplified PCR product was cloned into the pGEM-T easy vector (Promega), and the nucleotide sequence was determined.
Statistical Analysis. Student t test and one-way ANOVA were performed for data analysis by using SPSS 17.0 software (IBM). Log-rank analysis was used to determine statistical significance of Kaplan-Meier survival curve. For all statistical methods, P < 0.05 was considered significant. S4 . Two GSC subtypes display distinct growth kinetics in vitro. Graph indicating the average of the in vitro growth curves of PN (n = 4) and Mes (n = 5) GSC samples. Note that Mes GSCs grow substantially faster than PN ones (*P < 0.05, **P < 0.01). Data are from three independent experiments with similar results. Fig. S5 . IHC with the matched tumors from patients and mouse intracranial xenografts. Representative images of IHC for Olig2 (a PN marker) and CD44 (a Mes marker) on glioma tumor tissues from patients and mouse xenografts. Most of PN tumors from the patient and mice (528, 84, and 157) show high levels of Olig2 expression, whereas CD44 was at low levels. In contrast, strong IHC staining for CD44 (326, 1123, and 524) are found in most of Mes tumors but not PN tumors from patients and mice. Tumor sections were counter stained with hematoxylin (blue). 
